Skip to main content
. 2021 May 29;10(12):e019521. doi: 10.1161/JAHA.120.019521

Figure 5. Nanoparticle‐mediated simultaneous targeting of CypD and C‐C chemokine receptor 2 confer superior cardioprotection against IR injury.

Figure 5

*P<0.05, **P<0.01, 1‐way ANOVA. A, Gross appearance of left ventricle myocardial sections after Evans blue and triphenyltetrazolium chloride staining. B, The therapeutic effects of CsA‐NP, Pitava‐NP or CsA/Pitava‐NP on the infarct size in wild‐type mice with 30 or 60 minutes of ischemia followed by 24 hours of reperfusion. The data represent the mean±SD (n=8–9 per group). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, 1‐way ANOVA. C, The infarct‐sparing effects of CsA‐NP or Pitava‐NP in CypD‐knockout or CCR2‐knockout with 45 minutes of ischemia followed by 24 hours of reperfusion. The horizontal lines represent mean±SD (n=8 per group). CCR2‐KO indicates C‐C chemokine receptor 2‐knockout mice; CypD‐KO, cyclophilin D‐knockout mice; CsA‐NP, nanoparticles containing Cyclosporine A; FITC‐NP, nanoparticles containing fluorescein‐isothiocyanate; IR, ischemia‐reperfusion; Pitava‐NP, nanoparticles containing pitavastatin.